2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

Lyon AR., López-Fernández T., Couch LS., Asteggiano R., Aznar MC., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter DJ., de Azambuja E., de Boer RA., Dent SF., Farmakis D., Gevaert SA., Gorog DA., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger SS., Stephens R., Suter TM., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti CG., van der Meer P., van der Pal HJH., ESC Scientific Document Group None.

DOI

10.1093/ehjci/jeac106

Type

Journal article

Journal

Eur Heart J Cardiovasc Imaging

Publication Date

26/08/2022

Keywords

Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Anthracycline, Arrhythmias, Atrial fibrillation, Biomarkers, Cancer, Cancer survivors, Carcinoid syndrome, Cardiac magnetic resonance, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Coronary artery disease, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Strain, Thrombosis, Trastuzumab, Valvular heart disease, Vascular endothelial growth factor inhibitors (VEGFi), Venous thromboembolism

Permalink Original publication